Tirzepatide 7.5 mg: what happens at this dose?

Why does the dose increase to 7.5 mg rather than staying lower?

The titration schedule for tirzepatide is built around two competing goals: minimising gastrointestinal side effects while gradually reaching a dose that produces meaningful appetite suppression. The 2.5 mg starting dose exists almost entirely to settle your system, it has a mild effect on appetite, but its main job is adjustment. The 5 mg step builds on that. By the time 7.5 mg of tirzepatide is reached, your prescriber is looking for evidence that your body is tolerating the medicine well enough to go further.

Tirzepatide works by activating GIP and GLP-1 receptors, two gut-hormone pathways involved in satiety, blood-sugar regulation and gastric emptying. As the dose rises, the signal through those pathways strengthens. Many people report that at 7.5 tirzepatide, the sense of fullness after smaller meals becomes noticeably more reliable, less variable than it was at 5 mg. That said, responses vary considerably between individuals, and some people find the lower doses entirely sufficient. For context on what the full titration looks like from the beginning, the 2.5 mg page covers the starter phase in detail.

The NHS tirzepatide page confirms the six-strength UK schedule and describes how dose increases are managed with clinical oversight, worth reading alongside your Patient Information Leaflet.

What side effects are most common when moving to 7.5 mg?

Gastrointestinal effects are the ones most people notice. Nausea is the most frequently reported, followed by loose stools or constipation, indigestion, reflux and (for some) burping or fatigue in the first few days after an increase. These effects follow a predictable pattern: they tend to peak in the 24 to 72 hours after the first injection at a new dose, then ease. By the end of the second week at 7.5 mg, most people find they have largely settled.

Eating smaller meals, avoiding very fatty foods during the adjustment window and staying well hydrated all help. Injection-site reactions (mild redness, itching or a small lump) can occur with any dose; rotating between your abdomen, thigh and upper arm reduces this. Headache and dizziness are also reported by some people, usually briefly.

Rarely, pancreatitis can occur with GLP-1 and dual-agonist medicines. The MHRA issued a Drug Safety Update on this in January 2026: if you develop severe, persistent stomach pain that spreads to your back, with or without vomiting, stop the injection and seek urgent medical attention. That symptom needs same-day assessment, not a wait-and-see approach. Any suspected side effect can be reported directly to the MHRA Yellow Card scheme.

Pregnancy, breastfeeding and trying to conceive are situations where tirzepatide is not recommended. The medicine is not licensed for anyone under 18. These are firm clinical boundaries, not guidelines.

Does staying at 7.5 mg for longer than four weeks make sense?

Sometimes, yes. The titration schedule describes typical minimum intervals between increases (four weeks at each strength) but it is a floor, not a ceiling. If the 7.5 mg dose is producing good tolerability and steady progress, a prescriber may well recommend staying here rather than moving to 10 mg straight away. There is nothing in the clinical evidence suggesting faster titration produces better outcomes; it often produces worse tolerability.

People who have moved up quickly from 5 mg and found side effects significant are sometimes better served by consolidating at 7.5 mg for eight or even twelve weeks. The SURMOUNT-1 trial, published in the New England Journal of Medicine, showed that the highest average weight reductions were achieved at 10–15 mg over 72 weeks, but those results were built on a foundation of careful, well-tolerated titration, not speed. Reaching 15 mg quickly but tolerating it poorly is not a better outcome than staying at 7.5 mg and tolerating it well.

If you are considering where this sits in the broader picture of weight-loss treatment options, the weight-loss treatment overview explains how tirzepatide fits alongside other licensed medicines.

Can you get tirzepatide 7.5 mg through a private prescription?

Yes. Tirzepatide is licensed in the UK for private prescription for adults with a BMI of 30 or above, or 27 or above alongside a qualifying weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Eligibility is not determined by BMI alone, the prescriber considers the full picture, including your medical history and any medicines you already take.

Through nume, the process starts with a free consultation reviewed by a GPhC-registered prescriber on the day you submit it. There is no algorithm making decisions. Once approved, your order is dispatched the same day if submitted before 12pm, and DPD delivers it the next working day in plain, unbranded packaging, with a tracking notification on your phone so you know exactly when to expect it. The pen itself is a pre-filled KwikPen; each pen contains four weekly doses at the prescribed strength, beginning with 1 mg tirzepatide as the very first step before the schedule moves upward. If you are thinking about what private treatment typically costs, the Mounjaro pricing context page explains what drives the variation between providers honestly. For a full overview of what Mounjaro treatment involves from the first dose, including the 2.5 mg of tirzepatide that most people begin their journey on, the Mounjaro guide is the place to start. When you are ready to check whether you are eligible, start your free consultation here.